Quimigen Information

Quimigen Group, a European distributor of reagents and equipment for scientific research and medical diagnosis, has acquired Oncomedics, a French biotechnology company specialising in the personalisation of cancer treatments. For several years now, Quimigen Group has been supporting research and innovative start-ups in the health sector in various ways. Quimigen Group has decided to pursue its commitment by investing in Oncomedics, which has developed an in vitro diagnostic medical device, the Oncogramme ® . This tool provides oncologists with a decision-making aid to identify the most effective treatment combinations to treat a cancer patient. It is a functional test in oncology to determine the sensitivity of a patient's tumour to one or more anti-tumour agents. The principle consists of culturing patient's tumour cells and then placing them in the presence of different therapeutic molecules. The mortality of these tumour cells to the anti-tumour agents is then analysed. The first targeted indication is colon cancer and will soon be extended to other cancers such as breast cancer and ovarian cancer, in order to improve treatments by adapting them to each patient. « We are delighted that Oncomedics has joined Quimigen group. This partnership reflects our commitment to investing in scientific innovation. The Oncogramme ® will provide important information to oncologists and help improve patient treatment. We hope to develop this technology for several other cancers in the coming months , comments Tushendan Rasiah, CEO of Quimigen. « We are delighted to be joining Quimigen group, a leading European distributor of diagnostic reagents and services. Joining Quimigen group is a unique opportunity to have an environment conducive to the development of Oncograms to contribute to the improvement of treatments for various cancers comments Christophe Lautrette, CEO of Oncomedics.